Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analyst consensus: Seven analysts average a "Hold" rating on Galapagos (1 sell, 5 hold, 1 strong buy) with a 12‑month price target of $36.50.
• Institutional interest has risen recently—several funds initiated or increased positions and institutions now own about 32.46% of the stock.
• Share metrics: GLPG opened at $28, has a 12‑month range of $24.74–$37.78 and a market cap of $1.85 billion, while analysts expect the company to post a negative EPS (~‑6.97) for the current year.

Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have received an average recommendation of "Hold" from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $36.50.

A number of equities analysts have weighed in on GLPG shares. Wall Street Zen upgraded Galapagos from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. Raymond James Financial restated a "market perform" rating on shares of Galapagos in a research note on Tuesday, February 24th. UBS Group reaffirmed a "market perform" rating on shares of Galapagos in a report on Tuesday, February 24th. Weiss Ratings upgraded shares of Galapagos from a "sell (d)" rating to a "hold (c)" rating in a research note on Thursday, February 26th. Finally, Royal Bank Of Canada raised their price objective on shares of Galapagos from $32.00 to $33.00 and gave the stock a "sector perform" rating in a report on Tuesday, February 24th.

Hedge Funds Weigh In On Galapagos

Several institutional investors have recently made changes to their positions in the stock. State of Wyoming bought a new position in Galapagos in the 2nd quarter worth about $28,000. Van ECK Associates Corp raised its holdings in shares of Galapagos by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company's stock valued at $64,000 after buying an additional 750 shares during the last quarter. Arax Advisory Partners boosted its position in shares of Galapagos by 319.2% during the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company's stock worth $76,000 after buying an additional 1,778 shares during the period. Quadrant Capital Group LLC acquired a new position in shares of Galapagos during the third quarter worth approximately $134,000. Finally, Squarepoint Ops LLC bought a new position in Galapagos in the 3rd quarter worth approximately $211,000. 32.46% of the stock is owned by institutional investors.

Galapagos Price Performance

GLPG opened at $28.00 on Friday. Galapagos has a 12 month low of $24.74 and a 12 month high of $37.78. The business has a 50-day moving average of $30.81 and a two-hundred day moving average of $31.96. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -17.83 and a beta of 0.25.

Galapagos (NASDAQ:GLPG - Get Free Report) last issued its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. Equities research analysts anticipate that Galapagos will post -6.97 earnings per share for the current year.

Galapagos Company Profile

Galapagos NV NASDAQ: GLPG is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company's pipeline encompasses multiple programs across various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.